Given the cross-talk of the JAK/STAT, RAS/MAPK, and NF-κB pathways in MM pathogenesis, simultaneous inhibition of these pathways is considered a promising therapeutic approach for MM treatment. Here, NFKB1 is linked to Miyoshi myopathy.